Peptide ligands of class B G-protein-coupled receptors act via a two-step binding process, but the essential mechanisms that link their extracellular binding to intracellular receptor–arrestin interactions are not fully understood. Using NMR, crosslinking coupled to mass spectrometry, signaling experiments and computational approaches on the parathyroid hormone (PTH) type 1 receptor (PTHR), we show that initial binding of the PTH C-terminal part constrains the conformation of the flexible PTH N-terminal signaling epitope before a second binding event occurs. A ‘hot-spot’ PTH residue, His9, that inserts into the PTHR transmembrane domain at this second step allosterically engages receptor–arrestin coupling. A conformational change in PTHR intracellular loop 3 permits favorable interactions with β-arrestin’s finger loop. These results unveil structural determinants for PTHR–arrestin complex formation and reveal that the two-step binding mechanism proceeds via cooperative fluctuations between ligand and receptor, which extend to other class B G-protein-coupled receptors.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the same GPCR in living cells
Nature Communications Open Access 26 September 2022
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
All materials, data, and associated protocols will be made available to all qualified investigators from the corresponding authors upon reasonable request or with a simple institutional material transfer agreement. Source data are provided with this paper.
MS raw data have been deposited to MASSIVE (ftp://massive.ucsd.edu/MSV000084971/) under the project name ‘Allosteric interactions in the parathyroid hormone class B GPCR–arrestin complex formation’. Codes for NMR and MD simulations in this study are available from corresponding authors upon reasonable request.
de Graaf, C. et al. Extending the structural view of class B GPCRs. Trends Biochem. Sci. 42, 946–960 (2017).
Karageorgos, V. et al. Current understanding of the structure and function of family B GPCRs to design novel drugs. Hormones (Athens) 17, 45–59 (2018).
Castro, M., Nikolaev, V. O., Palm, D., Lohse, M. J. & Vilardaga, J. P. Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc. Natl Acad. Sci. USA 102, 16084–16089 (2005).
Kawai, M., Modder, U. I., Khosla, S. & Rosen, C. J. Emerging therapeutic opportunities for skeletal restoration. Nat. Rev. Drug Discov. 10, 141–156 (2011).
Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
Parthier, C., Reedtz-Runge, S., Rudolph, R. & Stubbs, M. T. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci. 34, 303–310 (2009).
Pioszak, A. A. & Xu, H. E. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc. Natl Acad. Sci. USA 105, 5034–5039 (2008).
Marx, U. C., Adermann, K., Bayer, P., Forssmann, W. G. & Rosch, P. Solution structures of human parathyroid hormone fragments hPTH(1-34) and hPTH(1-39) and bovine parathyroid hormone fragment bPTH(1-37). Biochem. Biophys. Res. Commun. 267, 213–220 (2000).
Zhao, L. H. et al. Structure and dynamics of the active human parathyroid hormone receptor-1. Science 364, 148–153 (2019).
Miao, Y., Bhattarai, A., Nguyen, A. T. N., Christopoulos, A. & May, L. T. Structural basis for binding of allosteric drug leads in the adenosine A1 receptor. Sci. Rep. 8, 16836 (2018).
Rana, S. & Sahoo, A. R. Model structures of inactive and peptide agonist bound C5aR: insights into agonist binding, selectivity and activation. Biochem. Biophys. Rep. 1, 85–96 (2015).
Zhang, C. et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387–392 (2012).
Song, W., Yen, H. Y., Robinson, C. V. & Sansom, M. S. P. State-dependent lipid interactions with the A2a receptor revealed by MD simulations using in vivo-mimetic membranes. Structure 27, 392–403.e3 (2019) .
Mouritsen, O. G. & Zuckermann, M. J. What’s so special about cholesterol? Lipids 39, 1101–1113 (2004).
Jin, L. et al. Crystal structure of human parathyroid hormone 1–34 at 0.9-Å resolution. J. Biol. Chem. 275, 27238–27244 (2000).
Bakan, A., Meireles, L. M. & Bahar, I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics 27, 1575–1577 (2011).
Eyal, E., Lum, G. & Bahar, I. The anisotropic network model web server at 2015 (ANM 2.0). Bioinformatics 31, 1487–1489 (2015).
Lezon, T. R. & Bahar, I. Constraints imposed by the membrane selectively guide the alternating access dynamics of the glutamate transporter GltPh. Biophys. J. 102, 1331–1340 (2012).
Doruker, P., Atilgan, A. R. & Bahar, I. Dynamics of proteins predicted by molecular dynamics simulations and analytical approaches: application to ɑ-amylase inhibitor. Proteins 40, 512–524 (2000).
Bahar, I., Lezon, T. R., Bakan, A. & Shrivastava, I. H. Normal mode analysis of biomolecular structures: functional mechanisms of membrane proteins. Chem. Rev. 110, 1463–1497 (2010).
Atilgan, A. R. et al. Anisotropy of fluctuation dynamics of proteins with an elastic network model. Biophys. J. 80, 505–515 (2001).
Dean, T., Vilardaga, J. P., Potts, J. T. Jr. & Gardella, T. J. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol. Endocrinol. 22, 156–166 (2008).
Ferrandon, S. et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat. Chem. Biol. 5, 734–742 (2009).
Sutkeviciute, I., Clark, L. J., White, A. D., Gardella, T. J. & Vilardaga, J. P. PTH/PTHrP receptor signaling, allostery, and structures. Trends Endocrinol. Metab. 30, 860–874 (2019).
Ehrenmann, J. et al. High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist. Nat. Struct. Mol. Biol. 25, 1086–1092 (2018).
Dror, R. O. et al. Activation mechanism of the β2-adrenergic receptor. Proc. Natl Acad. Sci. USA 108, 18684–18689 (2011).
Hamelberg, D., Mongan, J. & McCammon, J. A. Accelerated molecular dynamics: a promising and efficient simulation method for biomolecules. J. Chem. Phys. 120, 11919–11929 (2004).
Wang, Y., Harrison, C. B., Schulten, K. & McCammon, J. A. Implementation of accelerated molecular dynamics in NAMD. Comput. Sci. Discov. 4, 015002 (2011).
Fleetwood, O., Matricon, P., Carlsson, J. & Delemotte, L. Energy landscapes reveal agonist control of G protein-coupled receptor activation via microswitches. Biochemistry 59, 880–891 (2020).
Lovera, S., Cuzzolin, A., Kelm, S., De Fabritiis, G. & Sands, Z. A. Reconstruction of apo A2A receptor activation pathways reveal ligand-competent intermediates and state-dependent cholesterol hotspots. Sci. Rep. 9, 14199 (2019).
Isin, B., Schulten, K., Tajkhorshid, E. & Bahar, I. Mechanism of signal propagation upon retinal isomerization: insights from molecular dynamics simulations of rhodopsin restrained by normal modes. Biophys. J. 95, 789–803 (2008).
Vilardaga, J. P., Bunemann, M., Krasel, C., Castro, M. & Lohse, M. J. Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat. Biotechnol. 21, 807–812 (2003).
Oakley, R. H., Laporte, S. A., Holt, J. A., Caron, M. G. & Barak, L. S. Differential affinities of visual arrestin, βarrestin1, and βarrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275, 17201–17210 (2000).
Shukla, A. K. et al. Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 497, 137–141 (2013).
Kang, Y. et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523, 561–567 (2015).
Farrell, I. S., Toroney, R., Hazen, J. L., Mehl, R. A. & Chin, J. W. Photo-cross-linking interacting proteins with a genetically encoded benzophenone. Nat. Methods 2, 377–384 (2005).
Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296–W303 (2018).
Gardella, T. J. & Juppner, H. Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol. Metab. 12, 210–217 (2001).
Munk, C. et al. An online resource for GPCR structure determination and analysis. Nat. Methods 16, 151–162 (2019).
Sarkar, K. et al. Modulation of PTH1R signaling by an ECD binding antibody results in inhibition of β-arrestin 2 coupling. Sci. Rep. 9, 14432 (2019).
Gidon, A. et al. Endosomal GPCR signaling turned off by negative feedback actions of PKA and v-ATPase. Nat. Chem. Biol. 10, 707–709 (2014).
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005).
Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat. Methods 12, 7–8 (2015).
Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I. & Lomize, A. L. OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 40, D370–D376 (2012).
Lee, J. et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. J. Chem. Theory Comput. 12, 405–413 (2016).
Wu, E. L. et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997–2004 (2014).
Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781–1802 (2005).
Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71–73 (2017).
Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 27–38 (1996).
Bakan, A. et al. Evol and ProDy for bridging protein sequence evolution and structural dynamics. Bioinformatics 30, 2681–2683 (2014).
Hattersley, G., Dean, T., Corbin, B. A., Bahar, H. & Gardella, T. J. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157, 141–149 (2016).
Liang, Y. L. et al. Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor–Gs complex. Nature 555, 121–125 (2018).
Nikolaev, V. O., Bunemann, M., Hein, L., Hannawacker, A. & Lohse, M. J. Novel single chain cAMP sensors for receptor-induced signal propagation. J. Biol. Chem. 279, 37215–37218 (2004).
McGarvey, J. C. et al. Actin-sorting nexin 27 (SNX27)-retromer complex mediates rapid parathyroid hormone receptor recycling. J. Biol. Chem. 291, 10986–11002 (2016).
Liu, C. C. & Schultz, P. G. Adding new chemistries to the genetic code. Annu. Rev. Biochem. 79, 413–444 (2010).
Chin, J. W. et al. An expanded eukaryotic genetic code. Science 301, 964–967 (2003).
Serfling, R. & Coin, I. Incorporation of unnatural amino acids into proteins expressed in mammalian cells. Methods Enzymol. 580, 89–107 (2016).
Coin, I. et al. Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR. Cell 155, 1258–1269 (2013).
Gotze, M. et al. StavroX—a software for analyzing crosslinked products in protein interaction studies. J. Am. Soc. Mass Spectrom. 23, 76–87 (2012).
Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of General Medical Sciences, the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute on Drug Abuse of the US National Institutes of Health under grant awards nos. R01-DK111427, R01-DK116780 and R01-DK122259 (to J.-P.V.); DK011794 (to T.J.G.); P41-GM103712 and P30-DA035778 (to I.B.); R01-DA046939 (P.T.); and F31-AR074843 (to L.J.C.).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended Data Fig. 1 Two-dimensional 1H-15N transverse relaxation optimized spectroscopy (TROSY) spectra of 15N-PTH(1–34).
Spectra were obtained in the absence (blue) or presence of PTHRECD, 0.5 (pink) or 0.75 (purple) molar ratio. a, On the left panel, full spectra showing all peaks of PTH(1–34). On the right panel, spectra of Gly12 and Ser17. Ser17 peak was too weak to be seen at 0.75 molar ratio. b, Zoomed-in spectra showing most peaks of PTH(1–34). PTH(1–34) peaks are labeled with bold text, and peaks corresponding to attached Strep-tag are labeled with italicized text. c, Zoomed-in spectral region of PTH His9. The conformation of His9 in free PTH is marked by Peak #1. Peak #2 represents the new conformation of His9 that occurred in the presence of 0.5 molar ratio PTHRECD and becomes stronger at 0.75 molar ratio PTHRECD. d, Zoomed-in spectral region of PTH Asn16, showing PTH conformational changes in the presence of PTHRECD. Peak #1 represents the conformation of Asn16 in the free PTH. Peak #2 represents the new conformation of Asn16 when PTH is bound to PTHRECD.
Extended Data Fig. 2 TROSY peak intensity (height), peak intensity ratio (Ibound/Ifree), and chemical shift perturbation (Δδ).
a, Peak intensities (normalized with respect to the number of scans in TROSY experiments) varied along the PTH sequence and the variations increased upon binding to 0.5 and 0.75 molar ratios of PTHRECD due to reduced PTH flexibility. b, Peak intensity ratio (Ibound/Ifree) and c, Chemical shift perturbation (Δδ) of individual residues upon binding to 0.5 or 0.75 molar ratios of PTHRECD. Residue intensities from the same experiment were normalized with respect to the intensity of Ser3 (indicated by an arrow) prior to calculations in b. Residues 15–17, indicated by asterisks, do not have visible peaks in the presence of 0.75 molar ratio PTHRECD. The new peak at Asn16 in the presence of 0.75 molar ratio PTHRECD was not used for Ibound/Ifree analyses but is displayed in the chemical shift perturbation plot. PTH(1–34) is separated from residues in the linker and Strep-tag by a thin dashed line.
The NMR structural ensemble of free PTH(1–34) (cyan, PDB 1ZWA) was aligned onto MD snapshots of apo PTHR (dark green, see Methods for docking protocol). When the PTH ensemble is aligned onto PTHRECD oriented toward PTHRTMD, the N-terminal portion of PTH notably clashes with extracellular loops 1 and 2 (ECL1 and ECL2, colored purple and light orange, respectively). These clashes are reduced when the PTH ensemble is aligned onto PTHRECD oriented away from PTHRTMD.
a, Co-immunoprecipitation of HA-tagged PTHR and β-arrestins from HEK293 cells after stimulation with PTHWT. Stimulation with PTHH9A does not immunoprecipitate β-arrestin with PTHRHA. b, Averaged time courses of PTHR internalization after 60 s stimulation with 100 nM PTHWT or PTHH9A in HEK293 cells stably expressing PTHRSEP. Data represent the mean ± s.d. of N = 2 experiments with n = 18 cells per experiment (independent biological replicates). c, Radioligand competition assays of PTHWT and PTHH9A binding to PTHR R0 (G protein-free) conformation. d, Radioligand competition assays of PTHWT and PTHH9A binding to PTHR RG conformation. For c, d, data are averaged from N = 4 and N = 5 independent experiments, respectively. Square points and error bars represent mean ± s.e.m. Individual data points are also shown.
Extended Data Fig. 5 Interactions between PTHWT His9 side chain and PTHR residues, and comparison with the interactions of the mutant PTHH9A.
Panels a-e display MD snapshots of PTHWT-bound receptor, and panel f, those for the mutant H9A-bound receptor. PTHWT is cyan, and PTHR is green in panels a–e, and PTHH9A is light pink, and PTHR is hot pink in panel f. MD snapshots of PTHWT-bound receptor showing different interactions. a, His9 hydrogen bond with Tyr429 (ECL3). b, Hydrogen bonds with Ser355 and Gly357 main chain (ECL2). c, Hydrogen bond with Ser355 side chain (ECL2). d, Aromatic-aromatic interactions between His9 and Tyr429 (ECL3). e, Hydrogen bond with Gln364 (TM5). f, Interactions between PTHR Leu354 and PTHH9A Ala9 in triplicate simulations. MD snapshots were collected every 10 ns during the last 50 ns of each simulation are aligned by PTHRTMD (residues 180 to 460).
Snapshots of PTHWT- and PTHH9A-bound receptor collected during the last 50 ns of triplicate simulations (10 ns intervals), aligned by PTHR transmembrane helices. a, Aligned receptor structures, with dashed boxes indicating areas shown in b, c. The arrow points to the helical turn (residues 394 to 397) in ICL3. ECD (residues 27 to 179), ECL1 (residues 247 to 275), TM3 residues 276 to 280, and peptide residues 14 to 34 are hidden for clarity. b, ECL2 conformation. c, Left, relative inward movement of PTHH9A–PTHR TM5. Right, relative inward movement of PTHH9A–PTHR TM6. d, ICL3 conformations in PTHWT- and PTHH9A-bound receptor snapshots after one 200 ns simulation. The helical turn in ICL3 stabilized by PTHWT is indicated by an arrow.
a, Thr392-Val455 distance distributions over triplicate 200 ns simulations of apo, PTHWT-bound, and PTHH9A-bound receptor. Raw data are shown as thin lines. Second-order smoothed data (over 30 neighbors) are shown as thick lines. Top, plots starting at y = 0. Bottom, plots starting at y = 20. b, Alignment of PTHH9A-bound receptor (hot pink) TMD with the TMD of the PTHR–Gs cryo-EM structure. Gαs is colored purple. Clashing residues are shown as sticks. c, Interaction of PTHR Arg3965.75 with β-arrestin-1. In the PTHWT-bound model (green), positively charged Arg396 engages with negatively charged Glu155 and Glu156 from β-arrestin-1. In the PTHH9A-bound model (hot pink), Arg396 is oriented away from β-arrestin Glu155-156, toward Arg312. Since arginine side chains are flexible, Arg396 in the PTHH9A-bound model would reorient away from Arg312.
Two snapshots from 100 ns aMD simulation of apo PTHR were aligned by their transmembrane helices. The snapshot exhibiting the largest TM6 movement is colored dark green. The snapshot with the smallest TM6 displacement is colored yellow. a, Full receptor structures. b, Zoomed-in structures, with TM5, ICL3, and TM6 of each receptor indicated by colored arrows.
Extended Data Fig. 9 LC-MS/MS data identifying photo-crosslinking between PTHR and β-arrestin-1 F75Bpa in PTH-stimulated cells.
a, PTHR Thr392. b, PTHR Val384.
Supplementary Figs. 1–6 and Table 1.
Motion of PTHR in the presence of PTH. Receptor is shown in yellow (most of the structure) and red (from Arg390 to Leu481), and PTH is shown in green. Thr392 and Val455 are shown as black balls, and Leu354 and Ala9 as blue balls. The video illustrates the collective movement of the complex along ANM soft modes 3, 14 and 18.
Unprocessed blots for Supplementary Fig. 1b
NMR data (peak assignments, chemical shifts, peak intensities and relevant calculations)
R.m.s.d. from MD simulations
Statistical source data: (1) cAMP assay, (2) Barr recruitment
Statistical source data: (1) T392-V455 distances, (2) PTHR activation
Unprocessed western blots
Statistical source data: western blot band intensity plot
Statistical source data: (1) internalization assay, (2) binding assays
About this article
Cite this article
Clark, L.J., Krieger, J., White, A.D. et al. Allosteric interactions in the parathyroid hormone GPCR–arrestin complex formation. Nat Chem Biol 16, 1096–1104 (2020). https://doi.org/10.1038/s41589-020-0567-0